Exploratory Study Evaluating the Efficacy and the Tolerability of the Sequential Application of Two Marketed Products in Patients With Acne Vulgaris, Using a Split-Face Model

The aim of this proof of principle study is to evaluate efficacy and safety of the sequential application of two marketed products for the treatment of acne vulgaris, using the Split-Face model

开始日期2011-11-01

申办/合作机构

Leo Pharma, Inc.

100 项与维甲酸维E酯相关的临床结果

登录后查看更多信息

100 项与维甲酸维E酯相关的转化医学

登录后查看更多信息

100 项与维甲酸维E酯相关的专利（医药）

登录后查看更多信息

项与维甲酸维E酯相关的文献（医药）

2020-05-01·Lung Cancer2区 · 医学

Efficacy of immune check-point inhibitors (ICPi) in large cell neuroendocrine tumors of lung (LCNEC)

2区 · 医学

Article

作者: Dudnik, Elizabeth ; Rotem, Ofer ; Moore, Assaf ; Shochat, Tzippy ; Sherman, Shira ; Zer, Alona

OBJECTIVESLittle is known regarding the ICPi efficacy in LCNEC. We explored the efficacy and safety of ICPi in LCNEC and assessed its impact on OS.MATERIALS AND METHODSThirty-seven consecutive patients with advanced LCNEC were selected from the Davidoff Cancer Center database. These were divided into groups A1 (patients treated with ICPi, n-23) and A2 (patients not treated with ICPi, n-14). Additionally, group A1* was introduced (patients treated with ICPi as a monotherapy, n-21). Another cohort of advanced non-LCNEC lung cancer patients treated with nivolumab at five Israeli cancer centers was chosen as a comparator (group B, n-270). ORR, PFS with ICPi in group A1* were assessed (RECIST 1.1), OS with ICPi was compared between groups A1* and B. OS since advanced disease diagnosis (OSDx) was compared between groups A1 and A2.RESULTSIn group A1*, ORR and median PFS with ICPi were 33 %, and 4.2 months (95 % CI, 2.4-8.1), respectively. With median follow-up since start of ICPi of 6.2 months [IQR 2.2-12.1] and 4.9 months [IQR 2.3-8.9] in groups A1* and B, respectively, 52 % and 64 % of patients died in groups A1* and B, respectively. Median OS with ICPi comprised 11.8 months (95 % CI, 3.7-NR) and 6.9 months (95 % CI, 5.5-8.1) in groups A1* and B, respectively (p-0.23). Median OSDx was 14.5 months (95 % CI, 10.1-38.9) and 10.3 months (95 % CI, 2.6-NR), in groups A1 and A2, respectively (p-0.54).CONCLUSIONIn advanced LCNEC, ICPi outcomes are comparable to the outcomes observed in advanced NSCLC. Future research is needed to clarify the impact of ICPi on OS, and to correlate its benefit with tumor mutational landscape.

2013-10-01·Journal of Dermatological Science2区 · 医学

Reagents inducing epidermal proliferation also induce pigmentation: Induction of keratinocyte proliferation as a novel strategy for the treatment of vitiligo

2区 · 医学

Letter

作者: Mayumi Komine ; Mamitaro Ohtsuki ; Chieh-Shan Wu ; Yayoi Tada ; Kanako Kikuchi ; Seiki Fujimoto ; Hanako Ohmatsu ; Hsin-Su Yu ; Kunihiko Tamaki

A review.This article hypothesis the reagents inducing epidermal keratinocytes proliferation also induce pigmentation for treatment of vitiligo.The reagents used for proliferation are tacrolimus, alprostadil, alfadex, bendazac, etretinate, trafermin, phenytoin, bucladesine sodium, tretinoin tocoferil.

2013-01-01·Chemical & pharmaceutical bulletin

Physicochemical Characterization of Tretinoin Tocoferil Emulsion and Povidone-Iodine Sugar Ointment Blend Developed for Improved Regulation of Wound Moisture

Article

作者: Saito, Mika ; Watanabe, Kazuya ; Fujii, Satoshi ; Sanagawa, Akimasa ; Noda, Yasuhiro ; Sobajima, Yu

Maintenance of proper moisture and regulation of infection are simultaneously required to promote healing of pressure ulcers. Continuous use of water-rich ointment may often lead to excess moisture and induce edematous granulation tissue. Use of water soluble ointment may excessively absorb exudates and induce dry granulation tissue. Selection of appropriate topical ointment is desired to avoid worse clinical outcomes. For adjustment of wound moisture a novel blended ointment (tretinoin tocoferil-povidone-iodine (TR-PI)) was developed consisting of emulsion base, tretinoin tocoferil oil-in-water (o/w) emulsion (TR-cream), and sugar base, povidone-iodine and sugar (PI-sugar). For the characterization of TR-PI water absorption was tested using Franz diffusion cell with cellulose membrane. For rheological characteristics spreadability was tested using spread meter and yield value was calculated. Iodine permeation was tested using a permeation cell with silicon membrane. Water absorption rate constant of TR-PI with combination ratio of PI-sugar at 75% (TR-PI75, 18.5 mg cm(-2) min(-0.5)) was equivalent to that of TR-cream alone (16.4 mg cm(-2) min(-0.5)). The yield value of TR-PI75 (26.1 Pa) exhibited intermediate values as compared to those of TR-PI with combination ratio of PI-sugar at 50% (11.3 Pa) and TR-cream alone (46.8 Pa). The amount of released free-iodine from TR-PI75 was similar to that released from PI-sugar alone. TR-PI75 may have superior performance in keeping the moist environment in wounds and in preventing infection. TR-PI75 can be used to promote formation of favorable granulation tissue in pressure ulcers with moderate exudates.

100 项与维甲酸维E酯相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D01516	-	D10AD01 L01XX14	-

研发状态

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
褥疮	日本	Sun Pharmaceutical Industries Ltd.	1992-10-02
皮肤溃疡	日本	Sun Pharmaceutical Industries Ltd.	1992-10-02

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT01461655 (CTgov)	临床2期	寻常痤疮	40	vehicle gel+marketed topical retinoid (Topical Retinoid - Placebo)	窪積網鏇餘積網鬱壓壓(蓋膚衊窪齋鹹範鑰鹽憲) = 鑰選夢繭窪壓範夢積餘憲鹽鹹衊範壓積簾壓積 (淵簾膚鑰獵齋鏇壓糧壓, 築選餘簾膚鹹遞艱壓壓 ~ 積壓構憲遞構襯鬱鹹積) 更多	-	2013-12-04
				marketed topical NSAID+marketed topical retinoid (Topical Retinoid-NSAID)	窪積網鏇餘積網鬱壓壓(蓋膚衊窪齋鹹範鑰鹽憲) = 築廠壓築製網糧醖憲衊憲鹽鹹衊範壓積簾壓積 (淵簾膚鑰獵齋鏇壓糧壓, 範製齋鑰膚襯衊窪鏇衊 ~ 憲觸構鏇觸簾選願願鏇) 更多